Within the framework of the STEPUPIORS project, an excellent example of collaboration between academia and industry for the benefit of Serbian cancer patients took place in November 2023.
Company Novos d.o.o. kindly enabled the Institute for Oncology and Radiology of Serbia to acquire the first Luminex® MAGPIX® system in our country and try out simple, cost-effective medium-throughput multiplexing of @Merck MILLIPLEX® immunoassays on plasma samples of patients with locally advanced rectal cancer. Profiling of predictive biomarkers for the purpose of selection of patients who might benefit from the watch and wait approach enabling their higher quality of life will be performed. Validation of the results is planned on prospectively collected samples from the first Serbian rectal cancer biobank in 2024. Exciting times ahead!
